← Back to Screener
Vera Therapeutics, Inc. Class A Common Stock (VERA)
Price$42.24
Favorite Metrics
Price vs S&P 500 (26W)38.47%
Price vs S&P 500 (4W)7.57%
Market Capitalization$3.10B
All Metrics
Book Value / Share (Quarterly)$8.48
P/TBV (Annual)7.81x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.39
Price vs S&P 500 (YTD)-16.84%
EPS (TTM)$-4.66
10-Day Avg Trading Volume1.44M
EPS Excl Extra (TTM)$-4.66
EPS (Annual)$-4.66
ROI (Annual)-44.10%
Cash / Share (Quarterly)$10.03
ROA (Last FY)-40.78%
EBITD / Share (TTM)$-4.92
ROE (5Y Avg)-66.60%
Cash Flow / Share (Annual)$-3.39
P/B Ratio5.13x
P/B Ratio (Quarterly)5.87x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-3260.00x
ROA (TTM)-49.10%
EPS Incl Extra (Annual)$-4.66
Current Ratio (Annual)13.64x
Quick Ratio (Quarterly)13.48x
3-Month Avg Trading Volume1.27M
52-Week Price Return102.09%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.78
52-Week High$56.05
EPS Excl Extra (Annual)$-4.66
CapEx CAGR (5Y)44.50%
26-Week Price Return42.46%
Quick Ratio (Annual)13.48x
13-Week Price Return-6.48%
Total Debt / Equity (Annual)0.12x
Current Ratio (Quarterly)13.64x
Enterprise Value$2,820.517
Revenue / Employee (Annual)$0
Cash / Share (Annual)$10.03
3-Month Return Std Dev50.11%
Net Income / Employee (TTM)$-1
ROE (Last FY)-49.56%
Net Interest Coverage (Annual)-338.40x
EPS Basic Excl Extra (Annual)$-4.66
Total Debt / Equity (Quarterly)0.12x
EPS Incl Extra (TTM)$-4.66
ROI (TTM)-52.53%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.77
Price vs S&P 500 (52W)72.26%
Year-to-Date Return-14.20%
5-Day Price Return6.16%
EPS Normalized (Annual)$-4.66
ROA (5Y Avg)-45.08%
Month-to-Date Return8.00%
EBITD / Share (Annual)$-4.92
LT Debt / Equity (Annual)0.12x
ROI (5Y Avg)-52.60%
LT Debt / Equity (Quarterly)0.12x
EPS Basic Excl Extra (TTM)$-4.66
P/TBV (Quarterly)4.85x
P/B Ratio (Annual)5.87x
Book Value / Share (Annual)$8.48
Price vs S&P 500 (13W)-7.17%
Beta1.10x
Revenue / Share (TTM)$0.00
ROE (TTM)-59.72%
52-Week Low$18.76
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.15
4.15
4.15
4.25
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VERAVera Therapeutics, Inc. Class A Common Stock | — | — | — | — | $42.24 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Vera Therapeutics is a clinical-stage biotech company developing atacicept, a once-weekly subcutaneous fusion protein designed to treat serious autoimmune diseases. The drug works by blocking two key drivers of autoimmune dysfunction—B lymphocyte stimulator and APRIL—which reduces B cell and plasma cell activity and autoantibody production. The company is advancing atacicept through clinical development with a focus on transformative therapeutic potential in immunological disorders.